EXCELLENT RESEARCH
AND DEVELOPMENT CAPABILITIES
ROBUST R&D ENGINE
We have established a robust R&D engine, driven by our world-class team with a track record of prolific drug discovery, as well as a rigorous approach to discover novel and high-quality molecules by leveraging our multi-dimensional innovation-driving discovery platform.
—— bobapp下载地址_bob客户端下载_bob直播平台
Founders
Seasoned management team led by visionary founders with a proven track record of drug innovation and development, and backed by blue chip investors
Our mission
The discovery, Development, And Clinical Verification
We are committed to focus on discovery of next-generation candidates with improved efficacy and safety and low risks， so that patients can benefit as soon as possible.
small molecule precision oncology therapies & small molecule immuno-oncology therapies
Consists of a broad range of small-molecule
precision-oncology and immuno-oncology product candidates
News & Press
4 June, 2021, Shanghai – bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) today announced the app...
4 June, 2021, Shanghai – bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) announced the appointme...
25 May, 2021, Shanghai – bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) a clinical-stage biopha...
GUANGZHOU, China, April 29, 2021-- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burni...
December 14, 2020, Shanghai—bobapp下载地址_bob客户端下载_bob直播平台 Co., Ltd. (“Abbisko” hereafter) today announces that...
X4 Pharmaceuticals, a partner of bobapp下载地址_bob客户端下载_bob直播平台, recently presented positive biomarker, efficac...
We aspire to become a leading biopharmaceutical company that discovers and develops novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and globally.
Abbisko's investors including internationally renowned venture capital companies and domestic healthcare leaders provide support for the company's growth.
